WO2011022721A1 - Inhibiteurs des neurotoxines botuliques - Google Patents

Inhibiteurs des neurotoxines botuliques Download PDF

Info

Publication number
WO2011022721A1
WO2011022721A1 PCT/US2010/046314 US2010046314W WO2011022721A1 WO 2011022721 A1 WO2011022721 A1 WO 2011022721A1 US 2010046314 W US2010046314 W US 2010046314W WO 2011022721 A1 WO2011022721 A1 WO 2011022721A1
Authority
WO
WIPO (PCT)
Prior art keywords
botulinum neurotoxin
compound
formula
compounds
inhibitor
Prior art date
Application number
PCT/US2010/046314
Other languages
English (en)
Inventor
Terry L. Bowlin
Norton P. Peet
Michelle M. Butler
Steven C. Cardinale
Bing Li
Ramdas Pai
Original Assignee
Microbiotix, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbiotix, Inc filed Critical Microbiotix, Inc
Publication of WO2011022721A1 publication Critical patent/WO2011022721A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a pour objet des composés organiques présentant la capacité d'inhiber l'activité de la neurotoxine botulique. Les composés inhibiteurs de la neurotoxine botulique selon la présente invention sont utiles pour le traitement, la prévention, ou la réduction de l'intoxication de la neurotoxine botulique, en particulier de la neurotoxine botulique A et/ou B.
PCT/US2010/046314 2009-08-21 2010-08-23 Inhibiteurs des neurotoxines botuliques WO2011022721A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US27480909P 2009-08-21 2009-08-21
US61/274,809 2009-08-21
US32026810P 2010-04-01 2010-04-01
US61/320,268 2010-04-01
US37569410P 2010-08-20 2010-08-20
US61/375,694 2010-08-20

Publications (1)

Publication Number Publication Date
WO2011022721A1 true WO2011022721A1 (fr) 2011-02-24

Family

ID=43607363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/046314 WO2011022721A1 (fr) 2009-08-21 2010-08-23 Inhibiteurs des neurotoxines botuliques

Country Status (1)

Country Link
WO (1) WO2011022721A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603727A (zh) * 2012-02-29 2012-07-25 成都医学院 一种苯并噻唑衍生物的合成方法
CN103265478A (zh) * 2013-05-20 2013-08-28 中国人民解放军第二军医大学 巯基烟酸类化合物及其制备方法
WO2013129674A1 (fr) * 2012-03-01 2013-09-06 学校法人兵庫医科大学 Nouveau dérivé de benzimidazole et son utilisation
JP2014528412A (ja) * 2011-09-30 2014-10-27 キネタ・インコーポレイテツド 抗ウイルス化合物
EP3000807A4 (fr) * 2013-05-20 2017-01-04 Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, PR China Composé d'acide mercaptonicotinique, son procédé de préparation et son utilisation
WO2018010702A1 (fr) * 2016-07-12 2018-01-18 中国人民解放军军事医学科学院微生物流行病研究所 Composé d'acide nicotinique ou d'acide isonicotinique et utilisation associée
JP2018512447A (ja) * 2015-03-09 2018-05-17 アヴィディン・カンパニー・リミテッド ８−ヒドロキシキノリン誘導体のエナンチオマーとその合成
EP3388419A1 (fr) 2017-04-12 2018-10-17 Leadiant Biosciences SA Inhibiteurs de gli1 et utilisations associées
US10301265B2 (en) 2008-05-28 2019-05-28 Virginia I. Roxas-Duncan Small molecule inhibitors of botulinum neurotoxins
WO2020081856A1 (fr) * 2018-10-18 2020-04-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibiteurs de hiv-1 nef pour le traitement d'une infection par le vih
WO2021144794A1 (fr) 2020-01-13 2021-07-22 The Israel Institute of Biological Research (IIBR) Composés destinés à être utilisés dans le traitement et/ou la prévention de l'intoxication par des neurotoxines clostridiales

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203067A1 (en) * 2003-05-12 2005-09-15 Hresko Michelle C. Pesticidal compositions and methods
US20070112049A1 (en) * 2005-08-12 2007-05-17 Sina Bavari Small Molecule Inhibitors of Botulinum Neurotoxins
US20070270420A1 (en) * 2002-02-06 2007-11-22 Harbeson Scott L Heteroaryl compounds useful as inhibitors of gsk-3
EP1967517A1 (fr) * 2005-12-26 2008-09-10 Tohoku University Sonde de diagnostic d'une maladie conformationnelle
US20090010884A1 (en) * 2007-07-06 2009-01-08 Wyeth Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070270420A1 (en) * 2002-02-06 2007-11-22 Harbeson Scott L Heteroaryl compounds useful as inhibitors of gsk-3
US20050203067A1 (en) * 2003-05-12 2005-09-15 Hresko Michelle C. Pesticidal compositions and methods
US20070112049A1 (en) * 2005-08-12 2007-05-17 Sina Bavari Small Molecule Inhibitors of Botulinum Neurotoxins
EP1967517A1 (fr) * 2005-12-26 2008-09-10 Tohoku University Sonde de diagnostic d'une maladie conformationnelle
US20090010884A1 (en) * 2007-07-06 2009-01-08 Wyeth Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AKOS CONSULTING AND SOLUTIONS GMBH.: "Catalog entry AKL-PFR-137067. N-[4-(5-chloro-2- benzoxazolyl)phenyl]-2,3-dihydro-1,4-Benzodioxin-6-carboxamide.", 27 July 2009 (2009-07-27), Retrieved from the Internet <URL:http://www.akosgmbh.eu> *
BURNETT ET AL.: "A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease.", J MED CHEM, vol. 50, no. 9, 2007, pages 2127 - 2136 *
SILVAGGI ET AL.: "Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility.", CHEM BIOL., vol. 14, no. 5, 2007, pages 533 - 542, XP022087045, DOI: doi:10.1016/j.chembiol.2007.03.014 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10301265B2 (en) 2008-05-28 2019-05-28 Virginia I. Roxas-Duncan Small molecule inhibitors of botulinum neurotoxins
JP2014528412A (ja) * 2011-09-30 2014-10-27 キネタ・インコーポレイテツド 抗ウイルス化合物
WO2013127345A1 (fr) * 2012-02-29 2013-09-06 成都医学院 Composés utilisés en tant qu'inhibiteurs de la protéine kinase et leur utilisation
CN102603727A (zh) * 2012-02-29 2012-07-25 成都医学院 一种苯并噻唑衍生物的合成方法
US9212169B2 (en) 2012-03-01 2015-12-15 Hyogo College Of Medicine Benzimidazole derivative and use thereof
WO2013129674A1 (fr) * 2012-03-01 2013-09-06 学校法人兵庫医科大学 Nouveau dérivé de benzimidazole et son utilisation
JPWO2013129674A1 (ja) * 2012-03-01 2015-07-30 学校法人兵庫医科大学 新規ベンズイミダゾール誘導体及びその用途
EP3000807A4 (fr) * 2013-05-20 2017-01-04 Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, PR China Composé d'acide mercaptonicotinique, son procédé de préparation et son utilisation
CN103265478B (zh) * 2013-05-20 2015-09-30 中国人民解放军第二军医大学 巯基烟酸类化合物及其制备方法
CN103265478A (zh) * 2013-05-20 2013-08-28 中国人民解放军第二军医大学 巯基烟酸类化合物及其制备方法
JP2018512447A (ja) * 2015-03-09 2018-05-17 アヴィディン・カンパニー・リミテッド ８−ヒドロキシキノリン誘導体のエナンチオマーとその合成
US10287265B2 (en) * 2015-03-09 2019-05-14 Avidin Co. Ltd. Enantiomers of 8-hydroxyquinoline derivatives and the synthesis thereof
JP2021120391A (ja) * 2015-03-09 2021-08-19 アヴィディン・カンパニー・リミテッド ８−ヒドロキシキノリン誘導体のエナンチオマーとその合成
WO2018010702A1 (fr) * 2016-07-12 2018-01-18 中国人民解放军军事医学科学院微生物流行病研究所 Composé d'acide nicotinique ou d'acide isonicotinique et utilisation associée
US10981873B2 (en) 2016-07-12 2021-04-20 Academy Of Military Medical Sciences Nicotinic acid or isonicotinic acid compound and use thereof
EP3388419A1 (fr) 2017-04-12 2018-10-17 Leadiant Biosciences SA Inhibiteurs de gli1 et utilisations associées
WO2020081856A1 (fr) * 2018-10-18 2020-04-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibiteurs de hiv-1 nef pour le traitement d'une infection par le vih
WO2021144794A1 (fr) 2020-01-13 2021-07-22 The Israel Institute of Biological Research (IIBR) Composés destinés à être utilisés dans le traitement et/ou la prévention de l'intoxication par des neurotoxines clostridiales

Similar Documents

Publication Publication Date Title
WO2011022721A1 (fr) Inhibiteurs des neurotoxines botuliques
US20230148179A1 (en) SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF
CN102056483A (zh) 用于治疗或预防登革病毒感染的小分子抑制剂
CN105939716A (zh) 组蛋白脱乙酰基酶抑制剂和免疫调节药物的组合
CA2841487C (fr) Inhibiteurs du systeme de secretion bacterienne de type iii
US20120064062A1 (en) Inhibitors of bacterial plasminogen activators
EP2796450B1 (fr) Dérivés 6-aminopyridine-3-ol ou leurs sels pharmaceutiquement acceptables, et composition pharmaceutique contenant ces dérivés ou ces sels comme principes actifs pour la prévention ou le traitement des maladies provoquées par l&#39;angiogenèse
CA2757574C (fr) Inhibiteurs du systeme de secretion de type iii bacterien
CA3174438A1 (fr) Traitement d&#39;une infection a coronavirus
CN113289018A (zh) 金诺芬等老药及其组合物在抗单正链rna病毒中的应用
US20230233543A1 (en) Compounds for the treatment of covid-19
US11517581B2 (en) Zika virus protease inhibitors and methods of use thereof
EP2731600A2 (fr) Inhibiteurs du système de sécrétion bactérienne de type iii
CN103347539A (zh) 使用hiv蛋白酶抑制剂治疗系统性红斑狼疮的方法
WO2022106489A1 (fr) Composés pour le traitement et/ou la prévention d&#39;une infection à coronavirus
TW202218667A (zh) 血管收縮素轉化酶抑制劑之新用途-用於預防及治療嚴重特殊傳染性肺炎
EP3000807B1 (fr) Composé d&#39;acide mercaptonicotinique, son procédé de préparation et son utilisation
US20220226282A1 (en) Natural Product Antidotes against Botulinum Neurotoxins
JP2024512340A (ja) Ｃｏｖｉｄ－１９侵入阻害剤によるｃｏｖｉｄ－１９複製の抑制
US20230241067A1 (en) Targeting papain-like protease for broad-spectrum coronaviruses inhibition
EP4162932A1 (fr) Constituants hop antiviraux
US20230390235A1 (en) Therapeutic agent for covid-19
WO2024006949A2 (fr) Inhibiteurs allostériques de la protéase principale du sars-cov-2
WO2015143535A1 (fr) Inhibiteurs petites molécules inhibant une infection à vih médiée par gp120 et méthodes d&#39;utilisation
JPH02124818A (ja) 後天性免疫不全症侯群予防治療剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10810716

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 10810716

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE